熱門資訊> 正文
Apellis Pharmaceuticals宣布与Sobi达成一项有上限的版税购买协议，根据该协议，Apellis将获得高达3亿美元的Apellis未来Aspaveli在美国以外地区的版税的90%（系统性Pegcetacoplan）
2025-07-01 19:09
- Under the companies' 2020 collaboration agreement, Apellis is eligible for tiered royalties on ex-U.S. sales of Aspaveli ranging from high teens to high twenties. Apellis retains exclusive commercialization rights for systemic pegcetacoplan in the United States, where the product is marketed as EMPAVELI.
- Apellis to receive $275 million upfront and up to $25 million in milestone payments upon EMA approval in C3G and IC-MPGN
- Non-dilutive financing further strengthens Apellis' balance sheet
- Apellis retains full U.S. commercialization rights for systemic pegcetacoplan
- Transaction underscores shared confidence in the meaningful growth potential in rare kidney diseases
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
